Pemazyre Approved for Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Pemigatinib, a small molecule kinase inhibitor, selectively targets FGFR isoforms 1, 2 and 3, which, in preclinical studies, has resulted in anti-tumor activity in cells with FGFR alterations.